Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
10 Work Valuable chances to Assist with supporting Your Advanced degree - 2Yemen’s Aden airport shut by STC-backed transport minister, Saudi source says
- 3Collins Foods to offload 20 Taco Bell outlets in Australia
- 4The Tiny Channel Island With 65 Residents That Chefs And Foodies Go Out Of Their Way To Visit
- 5'Stranger Things' Season 5: When does Volume 2 come out? And Volume 3? Everything to know about the remaining episodes before the finale.
- IDF: Staying in West Bank refugee camps will quell lone-wolf terror
- Instructions to Clean and Really focus on Your Lab Precious stone
- 1st results from Blue Ghost lunar lander reveal how much we still don't know about the moon
- Europe pledges over €15bn for clean energy for Africa
- Meet the Stars of the Feline World: Well known Pet Feline Varieties
- Industrial zone damaged in Negev, falls in Sharon area after Iran fires missiles towards Israel
- COGAT discovers motor oil hidden inside UN's humanitarian aid to Gaza in smuggling attempt
- Slims down for Maintainable Weight reduction
- Top Pastry: What's Your Sweet Treat of Decision?
